Literature DB >> 24657400

Procoagulant imbalance in patients with non-alcoholic fatty liver disease.

Armando Tripodi1, Anna L Fracanzani2, Massimo Primignani3, Veena Chantarangkul4, Marigrazia Clerici4, Pier Mannuccio Mannucci5, Flora Peyvandi4, Cristina Bertelli2, Luca Valenti2, Silvia Fargion2.   

Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is characterized by increased risk of cardiovascular events and liver-fibrosis. Both could be explained by a procoagulant-imbalance that was surmised but never directly demonstrated. We investigated 113 patients with varying histological liver damage [steatosis (n=32), steatohepatitis (n=51), metabolic-cirrhosis (n=30)], 54 with alcoholic/viral-cirrhosis and 179 controls.
METHODS: Plasma was evaluated for levels of pro- and anti-coagulants, and for thrombin-generation assessed as endogenous-thrombin-potential (ETP) with and without thrombomodulin or Protac® as protein C activators. The procoagulant-imbalance was defined as ETP-ratio (with-to-without thrombomodulin) or as Protac®-induced-coagulation-inhibition (PICI%). High ETP-ratios or low PICI% indicate resistance to thrombomodulin or Protac® and hence a procoagulant-imbalance.
RESULTS: ETP-ratio increased from controls [0.57 (0.11-0.89)] to steatosis [0.72 (0.33-0.86)] and metabolic-cirrhosis [0.80 (0.57-0.95)], (p<0.001), the latter being comparable to that for alcoholic/viral-cirrhosis [0.80 (0.57-0.95) vs. 0.80 (0.44-0.96)]. Factor VIII (a potent procoagulant for thrombin-generation) increased from steatosis [99% (71-150)] to metabolic-cirrhosis [157% (64-232)], p<0.001. Protein C (a powerful anticoagulant) decreased from steatosis [103% (77-228)] to metabolic-cirrhosis [77 (17-146)], p<0.001. As a consequence, factor VIII-to-protein C ratio increased from steatosis [0.96 (0.36-1.60)] to metabolic-cirrhosis [2.05 (0.81-12.1)], p<0.001 and was correlated with the ETP-ratio (rho=0.543, p<0.001). Similar results were obtained for PICI%. Patients with procoagulant-imbalance detected as ETP-ratio greater or PICI% lower than the median value of controls tended to have a higher risk of metabolic-syndrome, higher intima-media thickness, fibrosis, steatosis or lobular inflammation, all considered clinical manifestations of NAFLD.
CONCLUSION: NAFLD is characterized by a procoagulant-imbalance progressing from the less severe (steatosis) to the most severe form of the disease (metabolic-cirrhosis). This imbalance appears to result from increased factor VIII and reduced protein C and might play a role in the risk of cardiovascular events and liver-fibrosis commonly observed in NAFLD.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Factor VIII; Protac®; Protein C; Thrombin generation; Thrombomodulin

Mesh:

Substances:

Year:  2014        PMID: 24657400     DOI: 10.1016/j.jhep.2014.03.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  45 in total

1.  Evaluation of high-fat high-fructose diet treatment in factor VIII (coagulation factor)-deficient mouse model.

Authors:  Alaknanda Mishra; Shailendra Arindkar; Preeti Sahay; Jerald Mahesh Kumar; Pramod K Upadhyay; Subeer S Majumdar; Perumal Nagarajan
Journal:  Int J Exp Pathol       Date:  2018-04-15       Impact factor: 1.925

Review 2.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

3.  Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer.

Authors:  Aida Moeini; Hiroko Machida; Tsuyoshi Takiuchi; Erin A Blake; Marianne S Hom; Toshio Miki; Osamu Matsuo; Koji Matsuo
Journal:  Clin Appl Thromb Hemost       Date:  2016-08-31       Impact factor: 2.389

Review 4.  Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2019-05-30

Review 5.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

6.  Pre-transplant portal vein thrombosis is an independent risk factor for graft loss due to hepatic artery thrombosis in liver transplant recipients.

Authors:  Jonathan G Stine; Shawn J Pelletier; Timothy M Schmitt; Robert J Porte; Patrick G Northup
Journal:  HPB (Oxford)       Date:  2015-12-10       Impact factor: 3.647

7.  Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.

Authors:  Yun-Hua Li; Lu-Hua Yang; Kai-Hui Sha; Tong-Gang Liu; Li-Guo Zhang; Xian-Xian Liu
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

8.  Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.

Authors:  Kuei-Chuan Lee; Wei-Fan Hsu; Yun-Cheng Hsieh; Che-Chang Chan; Ying-Ying Yang; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin
Journal:  Dig Dis Sci       Date:  2018-10-04       Impact factor: 3.199

Review 9.  Role of hemostatic factors in hepatic injury and disease: animal models de-liver.

Authors:  A K Kopec; N Joshi; J P Luyendyk
Journal:  J Thromb Haemost       Date:  2016-05-10       Impact factor: 5.824

Review 10.  Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .

Authors:  Naga Swetha Samji; Rajiv Heda; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.